



14 August 2025

Our Ref: FOI 1272

Dear

**Freedom of Information Act 2000
Information in relation to Myelofibrosis Treatment**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 7 July 2025. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Planning, Performance & Informatics Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Officer

Q1. Please provide the total number of patients treated in the last 6 months for:

- **Polycythaemia Vera (ICD10 code D45)**
- **Myelofibrosis (ICD10 code D47.4)**
- **Myelofibrosis (ICD10 code D47.4) patients aged 65 and older**

A1. Please see Table 1.

Please note, due to the current clinical coding time lag the latest available data for diagnostically coded discharged inpatients and day cases covers timeframe 01/04/2024 to 31/09/2024.

Please also note, the number of unique patients treated per diagnosis has been provided, note that a patient with more than one diagnosis code may be counted more than once across the rows within Table 1.

Table 1

Coding/Category	<65 Years	65 Years +	Total
Polycythaemia Vera (ICD10 code D45)	16	30	46
Myelofibrosis (ICD10 code D47.4)	Nil	15	15

Q2. How many patients were treated in the past 6 months (for any disease) with:

- **Ruxolitinib**
- **Fedratinib**
- **Momelotinib**

Q3. How many patients were treated with Ruxolitinib in the past 6 months for the following diseases?

- **Myelofibrosis (ICD10 code D47.4)**
- **Polycythaemia Vera (ICD10 code D45)**
- **Other/Unknown**

Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?

- **Of these patients, how many were treated in the past 6 months with Hydroxycarbamide?**
- **Of these patients, how many were treated in the past 6 months with Interferon therapy?**
- **Of these patients, how many have received no active treatment in the past 6 months?**

A. In response to questions 2, 3 & 4, the Trust is unable to specify the listed medicines from clinical coding either singly or collectively without including

additional false positives as these are grouped into a category of other high cost drugs.

Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

A5. No, the Trust does not participate in any clinical trials for the treatment of Myelofibrosis.